DE60128914D1 - Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation - Google Patents

Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation

Info

Publication number
DE60128914D1
DE60128914D1 DE60128914T DE60128914T DE60128914D1 DE 60128914 D1 DE60128914 D1 DE 60128914D1 DE 60128914 T DE60128914 T DE 60128914T DE 60128914 T DE60128914 T DE 60128914T DE 60128914 D1 DE60128914 D1 DE 60128914D1
Authority
DE
Germany
Prior art keywords
human origin
platelet aggregation
antibodies
inhibit platelet
iiia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60128914T
Other languages
English (en)
Other versions
DE60128914T2 (de
Inventor
Claudia Buettner
Meike Schwarz
Stefan Knackmuss
Karlheinz Peter
Peter Roettgen
Melvyn Little
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affimed GmbH
Original Assignee
Affimed Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed Therapeutics AG filed Critical Affimed Therapeutics AG
Application granted granted Critical
Publication of DE60128914D1 publication Critical patent/DE60128914D1/de
Publication of DE60128914T2 publication Critical patent/DE60128914T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
DE60128914T 2001-10-05 2001-10-05 Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation Expired - Lifetime DE60128914T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01123851A EP1300419B1 (de) 2001-10-05 2001-10-05 Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation

Publications (2)

Publication Number Publication Date
DE60128914D1 true DE60128914D1 (de) 2007-07-26
DE60128914T2 DE60128914T2 (de) 2008-05-08

Family

ID=8178855

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60128914T Expired - Lifetime DE60128914T2 (de) 2001-10-05 2001-10-05 Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation

Country Status (7)

Country Link
US (1) US7812136B2 (de)
EP (1) EP1300419B1 (de)
JP (2) JP4504017B2 (de)
AT (1) ATE364632T1 (de)
DE (1) DE60128914T2 (de)
ES (1) ES2288900T3 (de)
WO (1) WO2003031476A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002211658A1 (en) * 2000-10-13 2002-04-22 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
US8455627B2 (en) * 2001-10-05 2013-06-04 Affimed Therapeutics, Ag Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US8586033B2 (en) * 2003-12-03 2013-11-19 The Scripps Research Institute Integrin αIIbβ3 specific antibodies and peptides
CA2613691A1 (en) * 2005-07-05 2007-01-11 Baker Medical Research Institute Anticoagulation agent and uses thereof
WO2007139208A1 (ja) * 2006-05-26 2007-12-06 Kurume University 血小板の粘着凝集反応に関連する疾患の予防用又は治療用の医薬組成物、および、そのスクリーニング方法
US8563690B2 (en) 2008-11-03 2013-10-22 The Board Of Trustees Of The University Of Illinois Modulation of platelet aggregation
CA2762837C (en) 2009-05-20 2021-08-03 Novimmune S.A. Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
MX2013000301A (es) 2010-07-09 2013-05-09 Biogen Idec Hemophilia Inc Factores quimericos de coagulacion.
HUE049154T2 (hu) * 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
WO2012170969A2 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
AU2013270683A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Chimeric clotting factors
JP2015521589A (ja) 2012-06-08 2015-07-30 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． プロコアグラント化合物
CN103483452B (zh) * 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
KR101451340B1 (ko) * 2012-08-02 2014-10-15 (주)애드바이오텍 모발 생장 촉진용 조성물
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
EP3065769A4 (de) 2013-11-08 2017-05-31 Biogen MA Inc. Prokoagulatorische fusionsverbindung
CA3005158A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
AR105654A1 (es) * 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
JP6686768B2 (ja) * 2015-09-03 2020-04-22 東ソー株式会社 細胞の分離回収方法
LT3350220T (lt) 2015-09-15 2021-09-27 Scholar Rock, Inc. Anti pro/latentinio miostatino antikūnai ir jų panaudojimas
CN109071645A (zh) 2016-01-08 2018-12-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
KR102271635B1 (ko) 2016-06-13 2021-07-06 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
FI3565592T3 (fi) 2017-01-06 2023-05-10 Scholar Rock Inc Metabolisten tautien hoitaminen estämällä myostatiinin aktivaatio

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2776634B2 (ja) * 1991-09-17 1998-07-16 帝人株式会社 グリコプロテイン ▲ＩＩ▼ｂ／▲ＩＩＩ▼ａに対するヒト型モノクローナル抗体
AU6235294A (en) * 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing polypeptide binding sites
US6265150B1 (en) * 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
EP0990034A1 (de) * 1997-06-06 2000-04-05 Asat AG Applied Science & Technology Anti-gpiib/iiia rekombinante antikörper
CA2361877A1 (en) * 1999-03-01 2000-09-08 Genentech, Inc. Antibodies for cancer therapy and diagnosis

Also Published As

Publication number Publication date
DE60128914T2 (de) 2008-05-08
ES2288900T3 (es) 2008-02-01
JP2005514009A (ja) 2005-05-19
EP1300419B1 (de) 2007-06-13
EP1300419A1 (de) 2003-04-09
JP2010029203A (ja) 2010-02-12
JP4504017B2 (ja) 2010-07-14
US20070218067A1 (en) 2007-09-20
ATE364632T1 (de) 2007-07-15
US7812136B2 (en) 2010-10-12
WO2003031476A1 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
DE60128914D1 (de) Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
CY1113224T1 (el) Νεο αντισωμα αντι-ρlgf
CY1116632T1 (el) Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου
BRPI0511008A (pt) agentes de ligação de il-13
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
DE602006013029D1 (de) Anti-egfr-antikörper
RS54046B1 (en) ANTI-MIOSTATIN ANTITELA
BRPI0506679A (pt) métodos de tratar osteoartrite com antagonistas de il-6
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
ATE481979T1 (de) Kombination aus einem anti-edb-fibronectin- domänen-antikörper/il2-fusionsprotein und einem weiteren kleinen molekül
MX2009011407A (es) Antagonistas crig.
MX2010004615A (es) Anticuerpos monoclonales contra proteina c. activada e inactivada.
FR2897063B1 (fr) Polypeptides reconnus par des anticorps anti-trichinella, et leurs applications.
WO2004046188A3 (en) Anti-activated ras antibodies
IL177825A0 (en) Natural igm antibodies and inhibitors thereof
EE200300092A (et) EDb-fibronektiinidomeeni retseptor
BRPI0607499A2 (pt) combinação antitumor que compreende derivados de distamicina acriloìla substituìda e anticorpos que inibem fatores de crescimento ou seus receptores
WO2008048472A3 (en) Methods and compositions for stabilizing prostate specific antigen
ATE492564T1 (de) Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
UA98100C2 (ru) Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его
UA96426C2 (ru) Выделенное человеческое или гуманизированное антитело, которое специфически связывается с il-13
ITMO20050086A1 (it) 'dispositivo antifumo per sigarette o simili.'
TH89006B (th) การใช้ แพนตอน-วาเลนไทน์ ลิวโคซิดิน สำหรับการบำบัดและการป้องกันการติดเชื้อสเตปฟีโลคอคคัส
ES1061553Y (es) "dispositivo alargador-taladrador de gruesos variables".

Legal Events

Date Code Title Description
8364 No opposition during term of opposition